Skip to main content
Journal cover image

Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?

Publication ,  Journal Article
Gurbel, PA; Roe, MT; Jakubowski, JA; Shah, S; Erlinge, D; Goodman, SG; Huber, K; Chan, MY; Cornel, JH; Tantry, US; Ohman, EM
Published in: Thromb Haemost
July 2012

Translational platelet function investigations performed in the percutaneous coronary intervention (PCI)-treated population receiving clopidogrel have identified high platelet reactivity to ADP (HPR) as a major risk factor for both acute as well as long-term ischaemic event occurrence, including stent thrombosis. Recent studies have highlighted the relation of single nucleotide polymorphisms of genes involved in clopidogrel absorption and metabolism to reduced pharmacokinetic and pharmacodynamic responses to clopidogrel. CYP 2C19 loss-of-function (LoF) allele carriage has been associated with increased thrombotic risk in the PCI population. However, there is no information regarding the utility of platelet function testing to predict outcomes in patients with stable coronary artery disease and in medically managed patients with acute coronary syndromes. Additionally, few studies have included longitudinal assessment of platelet function to assess a potential time-dependent relation to ischaemic event occurrence and no phase-III antiplatelet-therapy trial has included a large enough platelet function sub-study to examine the relation between on-treatment platelet reactivity, bleeding, and ischaemic event occurrence. Therefore, futher studies are needed to delineate the role of platelet function testing across the spectrum of symptomatic coronary artery disease.

Duke Scholars

Published In

Thromb Haemost

DOI

EISSN

2567-689X

Publication Date

July 2012

Volume

108

Issue

1

Start / End Page

12 / 20

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Translational Research, Biomedical
  • Ticlopidine
  • Polymorphism, Genetic
  • Platelet Aggregation Inhibitors
  • Humans
  • Cytochrome P-450 CYP2C19
  • Coronary Artery Disease
  • Clopidogrel
  • Clinical Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gurbel, P. A., Roe, M. T., Jakubowski, J. A., Shah, S., Erlinge, D., Goodman, S. G., … Ohman, E. M. (2012). Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? Thromb Haemost, 108(1), 12–20. https://doi.org/10.1160/TH12-01-0039
Gurbel, Paul A., Matthew T. Roe, Joseph A. Jakubowski, Svathi Shah, David Erlinge, Shaun G. Goodman, Kurt Huber, et al. “Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?Thromb Haemost 108, no. 1 (July 2012): 12–20. https://doi.org/10.1160/TH12-01-0039.
Gurbel PA, Roe MT, Jakubowski JA, Shah S, Erlinge D, Goodman SG, et al. Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? Thromb Haemost. 2012 Jul;108(1):12–20.
Gurbel, Paul A., et al. “Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?Thromb Haemost, vol. 108, no. 1, July 2012, pp. 12–20. Pubmed, doi:10.1160/TH12-01-0039.
Gurbel PA, Roe MT, Jakubowski JA, Shah S, Erlinge D, Goodman SG, Huber K, Chan MY, Cornel JH, Tantry US, Ohman EM. Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? Thromb Haemost. 2012 Jul;108(1):12–20.
Journal cover image

Published In

Thromb Haemost

DOI

EISSN

2567-689X

Publication Date

July 2012

Volume

108

Issue

1

Start / End Page

12 / 20

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Translational Research, Biomedical
  • Ticlopidine
  • Polymorphism, Genetic
  • Platelet Aggregation Inhibitors
  • Humans
  • Cytochrome P-450 CYP2C19
  • Coronary Artery Disease
  • Clopidogrel
  • Clinical Trials as Topic